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SUMMARY
Fifty-two patients with severe and resistant psoriasis were treated with
8-methoxypsoralen followed by high intensity long wave ultraviolet light over a
12-month period at the Royal Victoria Hospital, Belfast. One hundred per cent
clearing of the plaques of psoriasis was obtained with an average dose of energy
of 53.5 joules in 43 (96 per cent) of 45 patients and the other two materially
improved. Seven are still in the clearing phase. Early side effects were uncommon.
There was no clinically significant change in laboratory or ophthalmological
findings. Of the nine patients who complained of arthritis, four had radiological
evidence and one showed radiological improvement after PUVA. In this study all
seven patients who had been using large doses of topically applied steroid cream
(up to 200 g Dermovate per week for two years) did not show adrenal suppression.
INTRODUCTION
Although the precise cause of psoriasis is unknown the characteristic lesions
are associated with epidermal proliferation and increased enzymatic and metabolic
activity. Attempts to control the rapid replication of cells by local application of
cytotoxic agents such as 5-thiouracil and nitrogen mustard have been largely
unsuccessful. Systemic cytotoxic agents, in particular methotrexate, have been
more successful. They inhibited DNA synthesis and thus provided a stimulus in
the search for other less toxic inhibiting agents. Psoralens in the presence of
UVA (320-400) were seen to inhibit DNA synthesis (Walter et al, 1973) and this
was extended when Parrish et al (1974) and later Wolff et al (1975) reported
successful treatment of psoriasis using the technique of photochemotherapy. This
involved the oral administration of 8-methoxypsoralen (8-mop) followed by
exposure tohigh intensity long wave ultraviolet light. This was an excellent
combination of two treatments, neither of which was effective on its own,
producing synergistic results. The spectrum of psoralens and photosensitization
lies within the UVA range, and as UVA requires 100 times more energy than
UVB to produce erythema this enables a more prolonged therapy. The treatment
was introduced in the Royal Victoria Hospital, Belfast, in September, 1977, and
the following is a report of a trial over one year.
48EXPERIMENTAL PROCEDURE
Selection of patients
Patients were selected for the trial under four groups:
Group A: patients unresponsive to conventional tar and dithranol therapy.
Group B: patients who had received large amounts of topically administered
steriods in whom it was hoped to prevent a flare-up when treatment
was abruptly discontinued.
Group C: patients receiving methotrexate with anticipation of withdrawal of
the drug.
Group D: patients with psoriasis confirmed to palms of the hands and soles
of the feet.
In addition, only those over the age of 18 were included in the trial.
Dosage of 8-methoxypsoralen
The drug was given to each patient on a weight related basis as shown in the
following schedule (Table 1).
TABLE I
Schedule for 8-MOP
Weight of patient Dose of 8-MOP
(kg) (mg)
<30 10
30-50 20
51-65 30
66-80 40
81-90 50
90+ 60
Equipment for UVA radiation
The system chosen was a Waldeman PUVA, 6,000 for a whole body radiation
with the Waldeman 200 for hands and feet.
Measuring the sensitivity of individual patients
This was done subjectively by skin typing and objectively by phototesting.
Skin typing was determined as shown in Table II.
TABLE II
Skin typing of patients in present series
Skin type History No. of patients
1 Always burn, never tan 13
2 Always burn, sometimes tan 17
3 Sometimes burn, always tan 19
4 Never burn, always tan 3
49Phototesting was performed on each patient. The minimal phototoxicity dose
(MPD) is the dose which produces barely perceptible but well defined erythema.
However, this does not forecast the patient's capacity to tan. Therefore a
patient with a high MPD and at a low sensitivity may tan very slowly and so
produce erythema to even small increases in UVA. As adjustments are necessary
because of increased tolerance to initial UVA dosage it is helpful to know the
patient's ability to develop pigmentation with respect to erythema. This is
calculated as a photosensitivity pigmentation index (PPI) as in Table III. As PPI
TABLE III
C E72 + C P120
PPI =
C E72 + C P120
Where
E E72 is the sum of all erythema readings at 72 hours.
C E120 is the sum of all erythema readings at 120 hours.
C P72 is the sum of all readings for pigmentation at 72 hours.
C P120 is the sum of all readings for pigmentation at 120 hours.
increases above 1 the greater the possibility of burning and consequently as it
decreases below 1 the greater the possibility of developing tolerance.
Treatment schedule
Each patient received treatment three times per week. There were three
variables, psoralen ingested, the UVA radiation and the patient's sensitivity to
PUVA. In the trial psoralen was kept constant on a weight related basis and the
other two factors were adjusted according to the individual response. The initial
dose of UVA was the minimal phototoxicity dose and those increments were
calculated from the PPI. When clearing was complete the patient was placed on
maintenance therapy, initially twice per week, reducing in some cases to one
treatment every two months. This interval was not exceeded as at this stage the
lesions developed accounting for not more than 5 per cent of the body surface.
The patient accepted these but it was felt that further reduction would result in
more widespread lesions. If the patient on maintenance PUVA developed psori-
asis on 5 per cent or more of the skin surface, he was restored to thrice weekly
treatment with a dose of UTVA as for last maintenance exposure. This was in-
creased as required.
Laboratory tests
Each patient had the following tests performed prior to commencing PUVA
therapy:- full blood picture, differential white cell count, erythrocyte sedimenta-
tion rate, block analysis - this included serum sodium, potassium, chloride, car-
bon dioxide, urea, calcium, cholesterol, glucose, bilirubin, alkaline phosphatase,
AST, ALT, total protein, albumin, uric acid, creatinine, creatine phosphokinase,
lactate dehydrogenase, iron and triglycerides. All these tests were repeated after
50six PUVA treatments, then after 12 and thereafter monthly or more frequently
depending on the uniformity of the results. The patient had a complete ophtha-
mological examintion initially, after six months and subsequently at six-monthly
intervals or earlier if requested by the ophthalmologist.
RESULTS
Table IV showss that satisfactory clearing of the lesions was obtained in pati-
ents in Groups A, B, and D, and indicates the frequency and dose required to
produce this outcome. It compares the results as regards number of exposures
and dosage with those in the literature. Satisfactory results have been obtained
here with a lower level of radiation.
Some more resistant cases are in the five in Group C who had been treated
with methotrexate. Three with psoriasis of 4 months, 21 and 22 years and treated
for 4 weeks, 2 years and 12 years with 7.5, 10.0 and 2.5 mg weekly, responded
to treatment comparable to those in Groups A, B and C. One affected for 30
years and treated with 7.5 mg methotrexate weekly for 1i years, although he has
now responded, required PUVA therapy for one year. The other patient with
psoriasis for 23 years had been treated with 15 mg weekly for two years and
failed objectively to respond to PUVA.
TABLE IV
Results of PUVA therapy in groups A, B, D, and results recorded by Melski
et al and Wolff et al
Average No. of
No. of Average No. Joules/cm2 at joules/cm2 to
Group patients of exposures last clearing produce clearing
A 20 23.52 55.35 4.15
Melski et al 23.6 251.0 11.8
Wolff et al 13.39 ± 7.08 66.1 ± 56.7
B 11 21.75 68.7 3.8
D 9 Hands 19.00 47.0 3.6
Feet 32.0 117.7 4.7
DISCUSSION
The dermatologists decided that the day-to-day management of the machine
would be best carried out by physiotherapists in their department and this has
worked well. The patients are routinely reviewed and their therapy regulated by
a dermatologist. The number of joules required to produce clearing in associa-
tion with the mean joules per cm squared at the last treatment compared to the
results obtained by Melski et al (1971) and Wolff (1978) is shown in Table IV.
The complications as a result of therapy may be short-term or long-term.
Short-term side effects which had been expected and those found in our series
are shown in Table V. The most troublesome side effect in the short-term was
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Complications in the present series
No. of patients
Eczema ... ... 5
Pruritus ...... ...... 12
Nausea ... ... 3
Ankle oedema ... 0
Pustules ... 0
Blisters ... 1
Herpes simplex ... 0
Acne vulgaris ... 3
pruritus. This, however, was easily controlled by an antihistamine. Nausea was
also a prominent symptom but again disappeared when PUVA was continued.
Long-term side effects must include eye complications such as cataracts and skin
cancer. No opinion about either may of course be given after one year's therapy.
There is still no evidence of skin neoplasm in any patient after treatment for two
years with PUVA.
All laboratory results showed no variation after PUVA therapy and it can be
concluder that PUVA in the short-term does not materially alter renal or hepatic
function. Of interest is the subjective improvement in arthritis noted in five
patients and in one of these there was radiological evidence of improvement. It is
also of note that three patients, all of whom were male, noted excessive hair
growth (anterior chest, beard area). The nail growth was measured for each of
these three men and was found to be within normal limits. Th-e plasma testos-
terone was also within normal limits for all patients. Of note, none of the patients
in this series showed the expected exacerbation when the topical corticosteroids
were abruptly discontinued and none showed evidence of adrenal suppression
even when applying Dermovate 200 g per week for two years.
CONCLUSION
PUVA is obviously a beneficial and effective therapy but what is worrying and
unpredictable in a long-term skin carcinogenic effect in view of its action on DNA
(Stern et al 1979). In this series 100 per cent clearing-was obtained with an average
dose of energy of only 53.5 joules as compared to 251 joules (Melski et al 1977)
(see Table IV). None of the patients developed skin cancer and this may be re-
lated to the lower dosage, but in addition no patient had a history of previous
skin neoplasm or radiation therapy. There is also the possibility of an effect on
elastic tissue, producing premature ageing. While these complications remain
uncertain the treatment must be kept under careful medical control, and obvious-
ly as a low dose of energy can produce 100 per cent clearing it is prudent to treat
the patients with this lower dose regime. At the moment there is no place for it
as a home therapy.
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